

Press release

November 18th, 2024

IMA Life, part of the IMA Group, announces strategic partnership with RheaVita to drive further technological development and commercial growth.

IMA Life makes a strategic investment in RheaVita and will support the company in advancing and commercializing its breakthrough continuous freeze-drying technology for biopharmaceutical products.

Ozzano dell'Emilia, Bologna, Italy - IMA Life, one of the three pharma divisions of IMA Group and global leader in advanced, aseptic pharmaceutical process and production solutions, is pleased to announce a strategic partnership with RheaVita, a pioneer in controlled, continuous freeze-drying technology for biopharmaceuticals. This partnership includes both a financial investment in RheaVita by IMA Life and ongoing support to expand the development and commercialization of RheaVita's cutting-edge technology for the global market.

IMA Life's commitment to technological innovation and excellence aligns closely with RheaVita's objectives, and the two companies are focused on driving impactful advancements in the freeze-drying market. *This partnership aligns with IMA Life's mission to support innovative technologies that enhance production efficiency and ensure consistent quality in life-saving therapies.* The common aim is to establish new standards in freeze-drying to benefit the global pharmaceutical industry and patients worldwide.

About IMA Life

IMA Life, part of the IMA Group, is a leading provider of advanced freeze-drying and aseptic processing solutions for the pharmaceutical sector. The company's comprehensive range of products and services supports pharmaceutical companies in achieving high-quality, efficient, and reliable manufacturing processes on a global scale. With decades of expertise, IMA Life remains at the forefront of innovation in pharmaceutical production, offering tailored solutions that meet the unique needs of each client.

For more information, please visit: <https://ima.it/pharma/brands/ima-life/>



About RheaVita

Founded in 2018 as a spin-off from Ghent University, RheaVita is dedicated to transforming the freeze-drying process in biopharmaceutical production. The company's continuous freeze-drying technology addresses the challenges of traditional methods by integrating all process steps into one streamlined, efficient system. RheaVita's technology enables rapid product and process development, flexible production capabilities, and superior product quality, making it ideally suited to produce precision medicines and other high-value therapies. With strong partnerships, RheaVita is committed to scaling its innovative technology for the global pharmaceutical industry.

For more information, please visit: www.rheavita.com

Contact information:

marketing.life.it@ima.it

info@rheavita.com

